-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network July 14 News On July 9, Sichuan Huiyu Pharmaceutical submitted and accepted the 4 types of generic listing application for cis-atracurium benzenesulfonate injection.
The product has been included in the fifth batch of national procurement, Hengrui Three domestic pharmaceutical companies won the bid
.
In recent years, Huiyu has aggressively attacked high-end injections.
Up to now, 7 injections submitted for production under the new classification have been approved and deemed to have been reviewed, and 6 are currently under review
.
The product has been included in the fifth batch of national procurement, Hengrui Three domestic pharmaceutical companies won the bid
.
In recent years, Huiyu has aggressively attacked high-end injections.
Up to now, 7 injections submitted for production under the new classification have been approved and deemed to have been reviewed, and 6 are currently under review
.
Figure 1: Latest product information declared
Source: CDE official website
Cisatracurium benzenesulfonate is a neuromuscular blocker that binds to cholinergic receptors on the motor endplate to antagonize the effect of acetylcholine, thereby producing competitive neuromuscular blockade.
It is suitable for Surgery and other operations and intensive care treatment
.
As an adjunct to general anesthesia or as a sedative in the intensive care unit (ICU), it can relax skeletal muscles and make tracheal intubation and device ventilation easier
.
It is suitable for Surgery and other operations and intensive care treatment
.
As an adjunct to general anesthesia or as a sedative in the intensive care unit (ICU), it can relax skeletal muscles and make tracheal intubation and device ventilation easier
.
According to data from Menet.
com, in 2019, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as China public medical institutions) terminals, the sales of paracuronium were close to 2.
8 billion yuan.
Affected by the epidemic, sales have declined.
The main products involve cisatracurium besylate injection and cisatracurium besylate injection
.
com, in 2019, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as China public medical institutions) terminals, the sales of paracuronium were close to 2.
8 billion yuan.
Affected by the epidemic, sales have declined.
The main products involve cisatracurium besylate injection and cisatracurium besylate injection
.
Figure 2: The competitive landscape of cisatracurium enterprises in 2020
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
From the perspective of corporate competition, Hengrui is currently leading this product, with a market share of 72% in 2020, and Aspen, the original research pharmaceutical company, only accounts for 0.
25%
.
In June 2021, the fifth batch of national procurement opened bids as scheduled, and cisatracurium benzenesulfonate injection was selected.
Finally, Hengrui, Nanjing Jianyou Biochemical Pharmaceuticals, and Hangzhou Aoya Biotech won the bids.
Shanghai Dongying (Jiangsu) Pharmaceutical, Zhejiang Xianju Pharmaceutical and Aspen, which together account for over 20% of the market, are expected to be further divided
.
25%
.
In June 2021, the fifth batch of national procurement opened bids as scheduled, and cisatracurium benzenesulfonate injection was selected.
Finally, Hengrui, Nanjing Jianyou Biochemical Pharmaceuticals, and Hangzhou Aoya Biotech won the bids.
Shanghai Dongying (Jiangsu) Pharmaceutical, Zhejiang Xianju Pharmaceutical and Aspen, which together account for over 20% of the market, are expected to be further divided
.
Table 1: Situation of injections declared and marketed by Huiyu
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Sichuan Huiyu pharmaceutical recent onslaught of high-end injection, as of now has seven approved products on the market, are anti- cancer drugs, injectable products in the trial are six, it relates to the field expanded to antiepileptic drugs, antiemetics and antinauseants Drugs, pituitary hypothalamus and similar drugs, and immunostimulants.
The contracted cisatracurium benzenesulfonate injection is a muscle relaxant
.
The contracted cisatracurium benzenesulfonate injection is a muscle relaxant
.
Source: CDE official website, Minet database
The review data statistics are as of July 13, if there are any errors or omissions, please correct me
.
.
Medical Network July 14 News On July 9, Sichuan Huiyu Pharmaceutical submitted and accepted the 4 types of generic listing application for cis-atracurium benzenesulfonate injection.
The product has been included in the fifth batch of national procurement, Hengrui Three domestic pharmaceutical companies won the bid
.
In recent years, Huiyu has aggressively attacked high-end injections.
Up to now, 7 injections submitted for production under the new classification have been approved and deemed to have been reviewed, and 6 are currently under review
.
The product has been included in the fifth batch of national procurement, Hengrui Three domestic pharmaceutical companies won the bid
.
In recent years, Huiyu has aggressively attacked high-end injections.
Up to now, 7 injections submitted for production under the new classification have been approved and deemed to have been reviewed, and 6 are currently under review
.
Figure 1: Latest product information declared
Source: CDE official website
Cisatracurium benzenesulfonate is a neuromuscular blocker that binds to cholinergic receptors on the motor endplate to antagonize the effect of acetylcholine, thereby producing competitive neuromuscular blockade.
It is suitable for Surgery and other operations and intensive care treatment
.
As an adjunct to general anesthesia or as a sedative in the intensive care unit (ICU), it can relax skeletal muscles and make tracheal intubation and device ventilation easier
.
It is suitable for Surgery and other operations and intensive care treatment
.
As an adjunct to general anesthesia or as a sedative in the intensive care unit (ICU), it can relax skeletal muscles and make tracheal intubation and device ventilation easier
.
According to data from Menet.
com, in 2019, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as China public medical institutions) terminals, the sales of paracuronium were close to 2.
8 billion yuan.
Affected by the epidemic, sales have declined.
The main products involve cisatracurium besylate injection and cisatracurium besylate injection
.
com, in 2019, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as China public medical institutions) terminals, the sales of paracuronium were close to 2.
8 billion yuan.
Affected by the epidemic, sales have declined.
The main products involve cisatracurium besylate injection and cisatracurium besylate injection
.
Figure 2: The competitive landscape of cisatracurium enterprises in 2020
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
From the perspective of corporate competition, Hengrui is currently leading this product, with a market share of 72% in 2020, and Aspen, the original research pharmaceutical company, only accounts for 0.
25%
.
In June 2021, the fifth batch of national procurement opened bids as scheduled, and cisatracurium benzenesulfonate injection was selected.
Finally, Hengrui, Nanjing Jianyou Biochemical Pharmaceuticals, and Hangzhou Aoya Biotech won the bids.
Shanghai Dongying (Jiangsu) Pharmaceutical, Zhejiang Xianju Pharmaceutical and Aspen, which together account for over 20% of the market, are expected to be further divided
.
25%
.
In June 2021, the fifth batch of national procurement opened bids as scheduled, and cisatracurium benzenesulfonate injection was selected.
Finally, Hengrui, Nanjing Jianyou Biochemical Pharmaceuticals, and Hangzhou Aoya Biotech won the bids.
Shanghai Dongying (Jiangsu) Pharmaceutical, Zhejiang Xianju Pharmaceutical and Aspen, which together account for over 20% of the market, are expected to be further divided
.
Table 1: Situation of injections declared and marketed by Huiyu
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Sichuan Huiyu pharmaceutical recent onslaught of high-end injection, as of now has seven approved products on the market, are anti- cancer drugs, injectable products in the trial are six, it relates to the field expanded to antiepileptic drugs, antiemetics and antinauseants Drugs, pituitary hypothalamus and similar drugs, and immunostimulants.
The contracted cisatracurium benzenesulfonate injection is a muscle relaxant
.
The contracted cisatracurium benzenesulfonate injection is a muscle relaxant
.
Source: CDE official website, Minet database
The review data statistics are as of July 13, if there are any errors or omissions, please correct me
.
.
Medical Network July 14 News On July 9, Sichuan Huiyu Pharmaceutical submitted and accepted the 4 types of generic listing application for cis-atracurium benzenesulfonate injection.
The product has been included in the fifth batch of national procurement, Hengrui Three domestic pharmaceutical companies won the bid
.
In recent years, Huiyu has aggressively attacked high-end injections.
Up to now, 7 injections submitted for production under the new classification have been approved and deemed to have been reviewed, and 6 are currently under review
.
The product has been included in the fifth batch of national procurement, Hengrui Three domestic pharmaceutical companies won the bid
.
In recent years, Huiyu has aggressively attacked high-end injections.
Up to now, 7 injections submitted for production under the new classification have been approved and deemed to have been reviewed, and 6 are currently under review
.
Figure 1: Latest product information declared
Source: CDE official website
Cisatracurium benzenesulfonate is a neuromuscular blocker that binds to cholinergic receptors on the motor endplate to antagonize the effect of acetylcholine, thereby producing competitive neuromuscular blockade.
It is suitable for Surgery and other operations and intensive care treatment
.
As an adjunct to general anesthesia or as a sedative in the intensive care unit (ICU), it can relax skeletal muscles and make tracheal intubation and device ventilation easier
.
Sports, sports, sportsIt is suitable for Surgery and other operations and intensive care treatment
.
As an adjunct to general anesthesia or as a sedative in the intensive care unit (ICU), it can relax skeletal muscles and make tracheal intubation and device ventilation easier
.
According to data from Menet.
com, in 2019, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as China public medical institutions) terminals, the sales of paracuronium were close to 2.
8 billion yuan.
Affected by the epidemic, sales have declined.
The main products involve cisatracurium besylate injection and cisatracurium besylate injection
.
Hospital hospital hospitalcom, in 2019, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as China public medical institutions) terminals, the sales of paracuronium were close to 2.
8 billion yuan.
Affected by the epidemic, sales have declined.
The main products involve cisatracurium besylate injection and cisatracurium besylate injection
.
Figure 2: The competitive landscape of cisatracurium enterprises in 2020
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
From the perspective of corporate competition, Hengrui is currently leading this product, with a market share of 72% in 2020, and Aspen, the original research pharmaceutical company, only accounts for 0.
25%
.
In June 2021, the fifth batch of national procurement opened bids as scheduled, and cisatracurium benzenesulfonate injection was selected.
Finally, Hengrui, Nanjing Jianyou Biochemical Pharmaceuticals, and Hangzhou Aoya Biotech won the bids.
Shanghai Dongying (Jiangsu) Pharmaceutical, Zhejiang Xianju Pharmaceutical and Aspen, which together account for over 20% of the market, are expected to be further divided
.
Enterprise business enterprise25%
.
In June 2021, the fifth batch of national procurement opened bids as scheduled, and cisatracurium benzenesulfonate injection was selected.
Finally, Hengrui, Nanjing Jianyou Biochemical Pharmaceuticals, and Hangzhou Aoya Biotech won the bids.
Shanghai Dongying (Jiangsu) Pharmaceutical, Zhejiang Xianju Pharmaceutical and Aspen, which together account for over 20% of the market, are expected to be further divided
.
Table 1: Situation of injections declared and marketed by Huiyu
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Sichuan Huiyu pharmaceutical recent onslaught of high-end injection, as of now has seven approved products on the market, are anti- cancer drugs, injectable products in the trial are six, it relates to the field expanded to antiepileptic drugs, antiemetics and antinauseants Drugs, pituitary hypothalamus and similar drugs, and immunostimulants.
The contracted cisatracurium benzenesulfonate injection is a muscle relaxant
.
Tumor tumor tumorThe contracted cisatracurium benzenesulfonate injection is a muscle relaxant
.
Source: CDE official website, Minet database
The review data statistics are as of July 13, if there are any errors or omissions, please correct me
.
.
